Traders should monitor for initial pricing and trading activity, but remain cautious due to lack of revenue, small clinical trial data, and high cash burn typical of early-stage biotechs. The effective IPO enables immediate share issuance, potentially leading to near-term dilution.
Price Chart
Executive Summary
Nasus Pharma's IPO registration has become effective, allowing the company to begin selling shares to the public. This follows a prior F-1 filing and confirms the company's entry into the public markets, though it remains a clinical-stage biotech with no revenue and substantial going concern risks.
Key Facts
- IPO registration (Form F-1) has become effective as of March 31, 2026.
- Company is a clinical-stage pharmaceutical firm focused on intranasal epinephrine (NS002) for emergency use.
- Has no revenue, significant accumulated losses, and disclosed substantial doubt about its ability to continue as a going concern.
- Raised $25 million through IPO and private placement, but faces high execution and funding risks.
- Development of naloxone candidate (NS001) has been paused to focus on lead product.
Financial Impact
$25 million raised via IPO and private placement
Risk Factors
- Substantial doubt about going concern status
- No revenue or near-term path to profitability
- Clinical trial data from small, underpowered studies
- High risk of future dilution as company seeks additional funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001019 |
| Document: 9999999995-26-001019-index.html | 9999999995-26-001019 |
| Document: 9999999995-26-001019.txt | 9999999995-26-001019 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.40 (−2.99%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.40 (−6.46%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.40 (+1.02%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.40 (−6.71%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.40 (−6.71%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.40 (−14.88%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.40 (−11.33%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.40 (−7.97%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.40 (−7.97%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.40 (−33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers